Study of ADI-PEG 20 in Patients With Advanced Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Metastatic MelanomaSkin CancerNeoplasm
Interventions
DRUG

ADI PEG 20

Intramuscular injections were administered into the deltoid, gluteal, or quadricep muscles once weekly (± 2 days) for 9 weeks during cycle 1 and 8 weeks during subsequent cycles

Trial Locations (2)

10016

NYU Cancer Institute, New York

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

collaborator

NYU Langone Health

OTHER

lead

Ludwig Institute for Cancer Research

OTHER